Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
by Press Release from Outbreak News Today on (#5Q57A)
NewsDesk @infectiousdiseasenews As the threat of resistance to current malaria treatment grows, Novartis and MMV have reported positive results of a new non-artemisinin combination in a Phase 2b study. The study tested ganaplacide, a novel agent with an entirely new mechanism of action, in combination with a new formulation of lumefantrine that is optimized for once daily dosing. [...]
The post Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria appeared first on Outbreak News Today.